Adviesraad voor Bioveiligheid Conseil consultatif de Biosécurité

Advice of the Belgian Biosafety Advisory Council on application GMFF-2022-3670 (genetically modified crop MON 89034 x 1507 x NK603) from Bayer and Corteva under Regulation (EC) No. 1829/2003

11 June 2024 Ref. SC/1510/BAC/2024 0799

Context

Application GMFF-2022-3670 was submitted by Bayer CropScience and Corteva AgriScience LLC. for the renewal of authorisation for the marketing of genetically modified (GM) maize MON 89034 x 1507 x NK603 (Unique Identifier MON-89Ø34-3 x DAS-Ø15Ø7-1 x MON-ØØ6Ø3-6) for food and feed uses, import and processing (excluding cultivation) within the European Union within the framework of Regulation (EC) No. $1829/2003^{1}$.

The placing on the market of the insect-resistant and herbicide-tolerant MON 89034 x 1507 x NK603 maize for food/feed uses, except cultivation, is currently authorised, following a positive opinion of EFSA (EFSA Journal 2010;8(9),1782)².

The renewal application was validated by EFSA on 3 May 2023 and a formal three-month consultation period of the Member States was started in accordance with Articles 6.4 and 18.4 of Regulation (EC) No. 1829/2003 (consultation of national Competent Authorities within the meaning of Directive 2001/18/EC designated by each Member State in the case of genetically modified organisms being part of the products).

Within the framework of this consultation, the coordinator for this dossier, on behalf of the Belgian Biosafety Advisory Council (BAC), decided not to request external experts to assess this dossier.

The scientific opinion of the EFSA Scientific Panel on GMOs was published on 26 April 2024 (EFSA Journal 2024;22(4):e8716)³, together with the responses from the EFSA GMO Panel to comments submitted by the Member States during the three-month consultation period.

The contents of the renewal application, the previous positive advice of the BAC on maize MON $89034 \times 1507 \times NK603 (BAC_2010_1160)^4$, and the published opinion of the EFSA GMO Panel form the basis of the advice of the BAC on application GMFF-2022-3670.

SC/1510/BAC/2024_0799

¹ Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed (OJ L 268, 18.10.2003, p.1).

² https://doi.org/10.2903/j.efsa.2010.1782

https://doi.org/10.2903/j.efsa.2024.8716

⁴ https://www.bio-council.be/sites/biocouncil.be/files/advices/BAC 2010 1160.pdf

Scientific evaluation

The data for application GMFF-2022-3670 provided by the applicant included:

- the annual post-market environmental monitoring (PMEM) reports covering the years of import,
- a systematic literature search covering the complete duration of the event's authorisation, and
- an updated bioinformatic package including (1) an analysis of the potential similarity of the newly
 produced proteins and newly created open reading frames within the insert or spanning the
 junctions with genomic DNA to known toxins or allergens, and (2) a safety assessment of the
 newly expressed protein Cry1A.105, Cry1F, Cry2Ab2, PAT, CP4 EPSPS and CP4 EPSPS
 L214P regarding its capacity to trigger celiac disease.

The Belgian experts and the members of the Biosafety Advisory Council did not identify any information elements in the renewal application GMFF-2022-3670 that would raise a safety concern for human or animal health or the environment.

Conclusion

The Biosafety Advisory Council is of the opinion that the data on maize MON $89034 \times 1507 \times NK603$ provided by the applicant, and the opinion of EFSA confirm its latest opinion that in the context of its proposed uses, maize MON $89034 \times 1507 \times NK603$, is unlikely to pose any risk to human and animal health and the European environment.

Dr. ir. Geert Angenon

President of the Belgian Biosafety Advisory Council